A Director at Aduro BioTech is Exercising Options

Yesterday it was reported that a Director at Aduro BioTech (ADRO), Ross Haghighat, exercised options to buy 55,539 ADRO shares at $0.63 a share, for a total transaction value of $35.53K.

Following this transaction Ross Haghighat’s holding in the company was increased by 17.92% to a total of $503.7K. In addition to Ross Haghighat, 4 other ADRO executives reported Buy trades in the last month.

See today’s analyst top recommended stocks >>

Based on Aduro BioTech’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $4.89 million and GAAP net loss of $18.58 million. In comparison, last year the company earned revenue of $2.64 million and had a GAAP net loss of $24.4 million. Currently, Aduro BioTech has an average volume of 515.88K. The company has a one-year high of $7.64 and a one-year low of $1.15.

Starting in June 2019, ADRO received 4 Buy ratings in a row.

In the last 30 days, insiders have sold $84.58K worth of ADRO shares and purchased $35.53K worth of ADRO shares. The insider sentiment on Aduro BioTech has been negative according to 18 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts